In a ground-breaking decision, the Food and Drug Administration approved the first gene therapies to treat patients with - a crippling condition that leaves sufferers in life-altering pain.On Friday, the administration gave the green light to Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients.Casgevy is the first FDA-approved treatment to use a type of novel gene editing technology called CRISPR. Lyfgenia uses conventional gene therapy - not gene editing - to treat the condition.
Load More
Load More